Dynamics of hormonal disorders following unilateral orchiectomy for a testicular tumor

Affecting mostly Caucasian males aged 15–40, testicular germ cell tumors represent the most common malignancy in this age group. Presenting symptoms usually include a testicular mass as well as lesions along the body mid-line (i.e., retroperitoneum, mediastinum or brain). Clinically divided into seminomas and non-seminomas, each group accounting for approximately 50%, they are a fine example of success in oncology. The prognosis remains excellent, especially in testicle-limited (stage I) tumors. Overall survival rates reach 99% for stage I seminomas. On the other hand, metastatic or relapsed disease does not preclude radical approach and chances for cure. Even in the ‘poor prognosis’ group of metastatic non-seminoma, 48–60% can still be cured with first-line chemotherapy [1]. Also older patients (>65 years) with germ cell tumors, believed to have a worse prognosis, achieve a survival rate as high as 72–83% [2]. Often combined with surgery and radiotherapy, chemotherapy has been the cornerstone of the treatment. New approaches such as high-dose chemotherapy with autologous stem cell transplant are being investigated to increase the survival rates in poor prognosis patients. Nevertheless, the clinical importance has now shifted from pursuing optimal treatment methods to closer follow-up of cancer survivors and an early diagnosis of late toxicities. As many as 24% of testicular cancer survivors develop overweight, 24%—hypercholesterolemia—and 30%—hypertension. Survivors with testosterone levels <4.3 ng/mL (22%) have an increased risk of the metabolic syndrome [3]. This effect is now attributed to the cumulative dose of cisplatin [4]. Uncompensated hypogonadism is characterized by the testosterone concentration below the lower limit of normal. In compensated hypogonadism, the testosterone concentration is within normal range, while the LH concentration exceeds the upper limit of normal. Impaired post-pubertal androgen function may cause infertility, sexual disorders, muscle weakness and bone demineralisation, as well as other metabolic disorders, depression and cognitive impairment [5, 6]. Male hypogonadism is defined as a syndrome of clinical symptoms resulting from androgen deficiency. It stems either from impaired function of the gonads (primary hypogonadism) or from hypothalamic–pituitary disorders at different levels (secondary hypogonadism). The most common causes of the primary hypogonadism are Klinefelter syndrome and testicular tumors [7, 8, 9]. The diagnosis of clinically significant testosterone (T) deficiency based solely on the total testosterone concentration is problematic. Total testosterone must exceed 3.50–4.00 ng/dL to reliably predict normal free testosterone [10]. According to the recommendations published in 2009 to be used in clinical practice, men with total serum of testosterone <2.31 ng/mL (8 mmol/L) should be treated with hormone replacement therapy. For men with total testosterone values between 2.31 and 3.46 ng/mL (8 and 12 mmol/L), treatment should be considered in the presence of symptoms associated with testosterone deficiency [11]. T (ng/mL)/LH (mIU/mL) ratio can facilitate the decision in men with borderline testosterone. The ratio reflects the complex nature of testosterone deficiency in adulthood that originates from hypothalamic–pituitary–gonadal axis disturbances. The T/LH ratio ≤1 correlates with the presence of testosterone deficiency symptoms [12]. Knowledge of hormonal disorders in patients treated for testicular tumor will allow to predict and possibly avoid metabolic consequences of hypogonadism. The aim of the paper is to evaluate the dynamics of hormonal changes in the pituitary–gonadal axis in adult men treated for testicular tumors.

One hundred twenty-eight patients with a unilateral testicular tumor were included in the study. The procedures had been approved by the Ethical Committee of Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.

The study was prospective, non-interventional. Written informed consent was obtained from each patient.

It has been estimated that the annual decrease in the circulating testosterone concentration is 0.2–2.0%. The percentage of middle-aged men presenting with hypogonadism is 6% [13]. In comparison, patients treated for a testicular malignancy performed worse. According to the literature, the risk of decreased testosterone concentration many years after a successful treatment of testicular tumors is 5–25% [8, 9, 14, 15, 16, 17, 18, 19, 20]. In contrast, it has also been reported that 10 years after orchiectomy testosterone concentrations do not differ from those in control groups [8]. All authors [8, 9, 14, 15, 16, 17, 18, 19, 20] agree that chronic compensated hypogonadism continues to be an issue even over 10 years after the completion of treatment [8]. According to other investigators, 24–75% of patients present with abnormal LH concentrations many years after the anticancer treatment. In addition, the upper range of the values given above seems to be better documented [16, 18, 19, 20]. In the presented material, the risk of pituitary-Leydig cell axis insufficiency increased over time, even after the completion of treatment. Moreover, the LH concentration seems to better reflect hormonal changes in men years after unilateral orchiectomy [8, 21]. The lowered testosterone/LH concentration ratio directly after orchiectomy may be a sign of a decrease in volume of the testosterone-releasing tissue after an LH stimulus. However, the subsequent decrease in this ratio should rather be interpreted as a decreased reactivity of Leydig cells in response to LH stimulation. This finding is confirmed by other authors [8, 21]. Luteinizing hormone and chorionic gonadotropin are morphologically similar polypeptide hormones stimulating the same receptor [22]. This fact explains the disruptive effect of high beta-hCG concentrations on the pituitary–gonadal axis. Other authors also suggest that hCG concentrations in testicular cancer patients correlate with testosterone, prolactin, estradiol and gonadotropins concentrations [23, 24, 25]. In our study, nearly 40% of the patients with active disease presented with elevated estradiol concentrations. In contrast, estradiol concentrations exceeded the normal limits in only 7% of patients without active disease. In the former group, we found a very strong correlation between the elevated estradiol concentrations and high beta-hCG concentrations. This justifies the statement that estradiol fulfills the criteria of a serum marker of the malignancy. According to other authors, an increasing estradiol concentration may predict a recurrence, even when other tumor markers remain within normal limits [26]. However, the role of estradiol as a tumor marker is still undetermined. Pathologically high estradiol concentrations interfere with the pituitary–gonadal axis, as confirmed by other authors [27, 28]. In the presented group of patients, abnormally high estradiol concentrations in the course of the disease were shown to have long-term consequences, increasing the risk of testosterone deficiency after treatment completion. The source of such high estradiol concentrations in patients with testicular tumors is unclear. There have been scarce data that estradiol may be secreted directly by the tumor, when exposed to chorionic gonadotropin [29, 30]. Another potential source of estradiol may be Leydig cells, stimulated by high hCG concentrations [30].

In our material, prolactin concentrations also changed significantly over time; this leads to a conclusion that prolactin balance is disrupted in patients with testicular tumors. Moreover, the balance is strongly dependent on hCG and estradiol concentrations, which has been confirmed in other papers [31]. The changes in hormone concentrations cannot be attributed only to unilateral orchiectomy. The clinical picture suggests that the tumor tissue also plays an important role in the endocrine balance through the paraneoplastic mechanism. Hypogonadism is a common problem in testicular cancer survivors. Yet, the need and principles of hormone supplementation are still to be established in further studies.

The study was limited by the fact that some of the patients were lost to follow-up. Similarly, the small number of patients included prior to orchiectomy could reduce the study’s power.

Changes in hormone concentrations in men treated for a unilateral testicular tumor are significant: LH and FSH concentrations increase in the course of treatment, while the concentrations of hCG, testosterone, estradiol decrease. Prolactin is the lowest at 1 month after orchiectomy. Pathologically high concentrations of chorionic gonadotropin and estradiol in these patients interfere with the pituitary–gonadal axis in a paraneoplastic mode.